Abstract. In the present study, we assessed the effects of gluco-obtusifolin, isolated from the seeds of Cassia obtusifolia L., and its aglycone, obtusifolin, on the learning and memory impairments induced by scopolamine using the passive avoidance and the Morris water maze tasks in mice. Gluco-obtusifolin (1, 2, and 4 mg/ kg, p.o.) and obtusifolin (0.25, 0.5, 1, and 2 mg/kg, p.o.) significantly reversed scopolamine-induced cognitive impairments in the passive avoidance test (P<0.05). Moreover, gluco-obtusifolin (2 mg/kg, p.o.) and obtusifolin (0.5 mg/kg, p.o.) improved escape latencies, swimming times in the target quadrant, and crossing numbers in the zone where the platform previously existed in the Morris water maze test. In the acetylcholinesterase assay, gluco-obtusifolin and obtusifolin were found to inhibit acetylcholinesterase activity in vitro (IC 50 = 37.2 and 18.5 μM, respectively) and ex vivo. These results suggest that gluco-obtusifolin and its aglycone may be useful for the treatment of cognitive impairment, and that its beneficial effects are mediated, in part, by the enhancement of cholinergic signaling.
Introduction
Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disorder and is now considered to be the most prevalent form of late-life mental failure in humans. In addition to the neuropathological hallmarks of this disease, namely, neurofibrillary tangles and neuritic plaques, AD is characterized neurochemically by a consistent deficit in cholinergic neurotransmission (1, 2) . The cholinergic receptor agonists and enhancers of the endogenous levels of acetylcholine have been examined as potential treatments for senile dementia of the Alzheimer type (3) . Of the various approaches investigated, acetylcholinesterase (AChE) inhibition was found to be the most successful; and as a result, the selective AChE inhibitor donepezil has been used for the treatment of mild or moderate AD (4 -6) .
Previously, we reported that the ethanolic extract of the seeds of Cassia obtusifolia L. (Leguminosae) (COE) has anti-amnesic effects on scopolamine-or transient cerebral hypoperfusion-induced memory impairment models (7) . By utilizing an activity-guided fractionation approach, we isolated several compounds including emodin and gluco-obtusifolin from COE. Glucoobtusifolin is an anthraquinone found in the seeds of Cassia obtusifolia, which are widely employed in traditional Chinese medicine. A small number of studies have addressed the pharmacological effects of glucoobtusifolin, but only two previous reports have suggested that gluco-obtusifolin or obtusifolin, aglycone of gluco-obtusifolin, has inhibitory effects on platelet aggregation and aldose reductase, respectively (8, 9) . However, no reports have been issued on the antiamnesic effects of gluco-obtusifolin. Thus, the present work was undertaken to characterize the ameliorating effect of gluco-obtusifolin and obtusifolin on scopolamine-induced memory impairment in mice using the passive avoidance and the Morris water maze tasks and to investigate the mode of action of each compound.
Materials and Methods

Animals
Male ICR mice (25 -30 g) were purchased from the Orient Co., Ltd., a branch of Charles River Laboratories (Seoul, Korea). Animals were housed 5 per cage, with food and water available ad libitum, and maintained under a constant temperature (23 ± 1°C) and humidity (60 ± 10%) under a 12-h light/ dark cycle (light on 07.30 -19.30 h). All behavioral tasks were conducted between 10:00 h and 16:00 h. Animal treatment and maintenance were carried out in accordance with the Principles of Laboratory Animal Care (NIH publication No. 85-23, revised 1985) and with the Animal Care and Use Guidelines of Kyung Hee University, Korea.
Materials
Tacrine (9-amino-1,2,3,4-tetrahydroacridine hydrochloride), (−)scopolamine hydrobromide, acetylthiocholine iodide, and 5,5'-dithio-bis-(2-nitrobenzoic acid) (DTNB) were purchased from the Sigma Chemical Co. (St. Louis, MO, USA). Gluco-obtusifolin and obtusifolin ( Fig. 1) were kindly donated by one of the authors (J.S. Choi). All other materials were obtained from normal commercial sources and were of the highest grade available.
Passive avoidance test
Passive avoidance test, which is a fear-motivated test classically used to assess short-term or long-term memory (10) , was carried out as described elsewhere (7) . The apparatus (Gemini Avoidance System, San Diego, CA, USA) was equipped with identical illuminated and non-illuminated boxes with a guillotine door (5 × 5 cm). The illuminated compartment (20 × 20 × 20 cm) contained a 50-W bulb, and the floor of nonilluminated compartment (20 × 20 × 20 cm) was composed of 2 mm stainless steel rods spaced 1 cm apart. A mouse was gently placed in the illuminated compartment for an acquisition trial, and the door between the two compartments was opened 10 s later. When the mouse entered the dark compartment, the door automatically closed and an electrical foot shock (0.5 mA, 3-s duration) was delivered through the stainless steel rods. Twenty-four hours after this acquisition trial, the mouse was again placed in the illuminated compartment for a retention trial. The time taken for a mouse to enter the dark compartment after door opening was defined as latency time for both acquisition and retention trials. Latency for entering the dark compartment was recorded up to 300 s. If a mouse did not enter the dark compartment within 300 s, the mouse was removed and assigned a latency score of 300 s. Gluco-obtusifolin and obtusifolin were dissolved in 10% Tween 80 solution, and tacrine and scopolamine were dissolved in 0.9% saline. Each drug was given 1 h before the acquisition trial. Memory impairment was induced in mice with scopolamine (1 mg/kg, i.p.) 30 min after each treatment. The control group received 10% Tween 80 solution only.
Morris water maze test
The Morris water maze test was conducted as described previously with minor modifications (7). The Morris water maze, which is used to measure the hippocampus-dependent spatial memory (11, 12) , is a circular pool (90 cm in diameter and 45 cm in height) filled with water (30 cm in depth) containing 5 g of black food coloring (20 ± 1°C). The tank was placed in a dimly lit, soundproof test room with various visual cues. A white platform (6 cm in diameter and 29-cm-high) was then placed in one of the pool quadrants. The first experimental day was dedicated to swimming training for 60 s in the absence of the platform. During the four subsequent days the mice were given four trials per day with the platform in place. When a mouse located the platform, it was permitted to remain on it for 10 s. If the mouse did not locate the platform within 60 s, it was placed on the platform for 10 s. After each trial the animal was returned to its home cage and allowed to dry under an infrared lamp. The time interval between each trial was 30 s. During each trial, the time taken to find the hidden platform (escape latency) was recorded using a video-based Ethovision System (Nodulus, Wageningen, The Netherlands). One day after the last training day, mice were subjected to a probe trial in which the platform was removed from the pool, allowing the mice to swim for 60 s to search for it. A record was kept on the swimming time in the pool quadrant where the platform had been previously placed, crossing number in the zone where the platform had previously been placed, and swimming speed. Gluco-obtusifolin and obtusifolin were dissolved in 10% Tween 80 solution, and tacrine and scopolamine were dissolved in 0.9% saline. Each drug was given 1 h before the first trial, every consecutive day. Memory impairment was induced in mice with scopolamine (1 mg/kg, i.p.) 30 min after each treatment. The control group received 10% Tween 80 solution only.
AChE inhibition assay
AChE activity was assayed using an acetylthiocholine iodide substrate based colorimetric method, as described elsewhere (13) . Whole brains of mice were homogenized in a glass Teflon homogenizer (Eyela, Tokyo) containing 50 volumes of homogenization buffer (12.5 mM sodium phosphate buffer pH 7.0, 400 mM NaCl) and then centrifuged at 1,000 × g for 10 min at 4°C. The supernatant was used as the enzyme source. Gluco-obtusifolin, obtusifolin, or tacrine was dissolved in 0.1% DMSO solution and diluted to various concentrations in Buffer A (100 mM sodium phosphate buffer, pH 8.0) immediately before use. An aliquot of diluted gluco-obtusifolin, obtusifolin, or tacrine solution in Buffer A (1.5 ml) was then mixed with 2.6 ml of Buffer A, enzyme source (400 μl), and 100 μl of buffered Ellman's reagent (10 mM DTNB and 15 mM sodium bicarbonate) and reacted at room temperature for 30 min. Absorbance was measured at 410 nm immediately after adding the 20 μl of acetylthiocholine iodide solution (75 mM) to the reaction mixtures (OPTIZEN 2120UV; Mecasys Co., Ltd., Daejeon, Korea). Readings were taken at 30-s intervals for 5 min. For the ex vivo studies, mice were treated with vehicle (10% Tween 80 solution), gluco-obtusifolin (2 mg/kg, p.o.), obtusifolin (1 mg/kg, p.o.), or tacrine (10 mg/kg, p.o.). The mice were decapitated 1 h after each treatment, and the brains were removed. AChE activities were determined as described above.
Statistics
Passive avoidance task results were analyzed using the Kruskal-Wallis non-parametric test; and when the results were found to be significant, treatment groups were compared using Tukey's post hoc test. In particular, group differences of escape latency in the Morris water maze task were analyzed using two-way analysis of variance (ANOVA) with repeated measures. In the case of AChE activities and swimming time, crossing number, and swimming speed in the probe trial of the Morris water maze task, data were analyzed by one-way ANOVA followed by Tukey's post hoc test for multiple comparisons. Statistical significance was set at P<0.05.
Results
Effects of gluco-obtusifolin and obtusifolin on memory impairment induced by scopolamine in the passive avoidance test
Gluco-obtusifolin was found to have a significant group effect in terms of step-through latency in the retention trial [H(6) = 48.114, P<0.001] (Fig. 2A) . The mean step-through latency of the scopolamine-injected group was significantly shorter than that of the control group (P<0.05). Moreover, the reduction in step-through latency induced by scopolamine was significantly reversed by gluco-obtusifolin (1, 2, and 4 mg/kg) treatment (P<0.05, Fig. 2A) .
Next, to determine if obtusifolin, the aglycone of obtusifolin, also has an ameliorating effect on cholinergic dysfunction-induced memory impairment like gluco-obtusifolin, we tested the effect of obtusifolin on the passive avoidance task. Obtusifolin was found to have a significant group effect in terms of stepthrough latency in the retention trial [H(6) = 37.590, P<0.001] (Fig. 2B) . The reduction in step-through latency induced by scopolamine was reversed by obtusifolin (0.25, 0.5, 1, and 2 mg/ kg) administration (P<0.05, Fig. 2B ). Latency time during the acquisition trial was not affected by scopolamine or drug treatments. According to these data, we adopted the maximum effective doses of gluco-obtusifolin and obtusifolin as 2 and 0.5 mg/kg, respectively, for further study. (Fig. 3C) in the zone where the platform previously existed. During the probe trial session, swimming times and crossing numbers in the scopolamine-treated group were significantly lower than those in the vehicle-treated control group (Fig. 3 : B and C, P<0.05). The shorter swimming times and crossing numbers induced by scopolamine were significantly reversed by gluco-obtusifolin, obtusifolin, and tacrine ( Fig. 3 : B and C, P<0.05). However, no significant differences in swimming speed within the target quadrant were observed between the groups (Fig. 3D) , which demonstrated that gluco-obtusifolin and obtusifolin had no effect on general locomotor behavior.
Effects of gluco-obtusifolin and obtusifolin on AChE activity
To investigate the mode of action of gluco-obtusifolin and obtusifolin, their AChE inhibitory activities were assessed using mouse brain homogenates. It is well known that the anti-amnesic effects of tacrine and donepezil are due to AChE inhibition in the brain (14, 15) . Tacrine (a positive control) inhibited AChE activity with an IC 50 of 96.6 nM in mouse brain homogenates (Fig. 4A ), which concurs with the previous data (16). Gluco-obtusifolin and obtusifolin also inhibited AChE activity in a concentration-dependent manner (IC 50 = 37.2 and 18.5 μM, respectively; Fig. 4A ). Furthermore, our ex vivo study showed that gluco-obtusifolin (2 mg /kg, p.o.), obtusifolin (0.5 mg/kg, p.o.), and tacrine (10 mg/kg, p.o., positive control) significantly blocked AChE activity 1 h after each administration [F(3,8) = 6.234, P = 0.017; Fig. 4B ].
Discussion
In the present study, we tested the effects of glucoobtusifolin and its aglycone, obtusifolin, on a scopolamine-induced memory impairment mouse model using the passive avoidance and the Morris water maze tasks. Gluco-obtusifolin and obtusifolin exhibited an antiamnesic effect on the scopolamine-induced memory impairment model in both of these tests. Moreover, in the AChE inhibition assay, gluco-obtusifolin and obtusifolin exerted potent inhibitory activities both in vitro and ex vivo. These results suggest that they have an ameliorating effect on the cholinergic dysfunctioninduced memory impairment model by enhancing cholinergic transmission.
Current AChE inhibitors such as donepezil and rivastigmine offer only a modest benefit. Although a disease-modifying therapy for AD will probably reduce the number of patients by nearly 50%, true diseasemodifying drugs are on the horizon (17) . Therefore, up to now, AChE inhibition is still the most successful intervention for mild AD. Previously, we proposed that COE could be a potential therapeutic agent for cholinergic dysfunction (7) and neurodegenerative disorders (18) . Based on these previous investigations, we wanted to clarify which compound(s) in COE plays a key role in its anti-amnesic activity. The seeds of Cassia obtusifolia contain several anthraquinones such as physcion, chrysophanol, emodin, gluco-obtusin, and gluco-obtusifolin (9). As mentioned above, we isolated several compounds, including gluco-obtusifolin, obtusifolin (aglycone of gluco-obtusifolin), rubrofusarin 6-Ogentiobioside, and emodine. Emodine was reported to have a beneficial effect on cycloheximide-induced memory consolidation impairment via the serotonergic nervous system, but not via the cholinergic nervous system (19) . In agreement with this report, we also observed that emodin has ameliorating effects on scopolamine-induced memory impairment in mice, but does not have any inhibitory activities on AChE in vitro or ex vivo (data not shown). We also identified rubrofusarin 6-O-gentiobioside from COE (7) and found that it exhibited moderate ameliorating activities against the scopolamine-induced memory deficit model (data not shown). Thus, emodine and rubrofusarin 6-Ogentiobioside could be excluded from the active com- pounds that play a key role in the anti-amnesic activity of COE through AChE inhibition.
Structurally, gluco-obtusifolin and obtusifolin are very similar to emodin or rubrofusarin. In the passive avoidance and the Morris water maze tasks, contrary to rubrofusarin 6-O-gentiobioside, gluco-obtusifolin ameliorated memory impairments induced by scopolamine, which was competitive with tacrine as a positive control. Similar activities of obtusifolin were also observed, although the maximum effective dose of obtusifolin on the passive avoidance task was lower than that of gluco-obtusifolin. AChE inhibition concentration of obtusifolin was also lower compared to glucoobtusifolin. In addition, although gluco-obtusifolin or obtusifolin was less potent than tacrine in terms of its in vitro AChE activity, it was found to be similar to tacrine in terms of its in vivo memory-related behavior. These results indicate that the ameliorative activities of glucoobtusifolin on memory dysfunction are not only dependent on its AChE inhibitory activities. It could be speculated that gluco-obtusifolin or obtusifolin acts as cholinergic agonist. However, it seems that either compound does not exhibit any positive binding activities to muscarinic receptors even at a concentration 10 μM (data not shown). Taken together, we suggest that gluco-obtusifolin or obtusifolin is an active compound of COE that has ameliorating effects on memory dysfunction and AChE inhibitory effects. However, since the actual content of gluco-obtusifolin in COE was lower than that of rubrofusarin 6-O-gentiobioside in COE (data not shown) and the inhibitory activity of gluco-obtusifolin or obtusifolin on AChE was weak, further research is needed to clarify these issues.
Plant glycoside has been proposed to act as a prodrug that is metabolized to its active form by intestinal bacterial deglycosylation (20) . This concept has been applied to several plant glycosides including ginsenosides from Gindeng Radix (21), rhaponticin from Rhei Rhizome (22) , and stevioside from Stevia (23), which means that orally treated glycoside is usually absorbed after being hydrolyzed to its corresponding aglycone by intestinal microflora. Although we did not confirm the fate of gluco-obtusifolin by intestinal microflora, similar pharmacological effects of gluco-obtusifolin and obtusifolin in vivo suggest that gluco-obtusifolin may be active by intestinal bacterial deglycosylation. It is unclear why the differences of effective doses between gluco-obtusifolin and obtusifolin on the passive avoidance test were much greater than the differences of inhibitory concentrations on the AChE activity. However, we can speculate that gluco-obtusifolin might not be totally metabolized into obtusifolin in the intestine; and therefore, a higher amount of glucoobtusifolin was required to exhibit similar activity in the passive avoidance test, albeit the effective blood concentration would be the same. Further studies are thus needed to clarify its metabolic pathway in the intestinal tract and its bioavailability.
If a compound has an AChE activity and other beneficial effects on neurodegenerative disease including an anti-oxidative effect, it could be a new generation and excellent drug candidate for AD therapy. Previously, gluco-obtusifolin or obtusifolin has been reported to have potential inhibitory activity against platelet aggregation (8) , although its activity on platelet aggregation has not been confirmed in vivo. Whereas characterizations are still on their way, one could speculate that gluco-obtusifolin may also be applied to vascular dementia since anti-platelet therapy has been shown to reduce the incidence or recurrence of stroke (24) . In addition, one of the authors (J.S. Choi) also reported that gluco-obtusifolin has marginal inhibitory and scavenging activities for total reactive oxygen species generation and for peroxynitrite (25) . Although the present and other findings do not provide clinically useful outcome data in humans, they do suggest that gluco-obtusifolin or obtusifolin can be viewed as a lead compound for anti-amnesic drug development.
